The University of Cambridge successfully tested the first vaccine antigen designed exclusively by artificial intelligence. This approach bypasses traditional trial-and-error methods to identify effective protein structures. Researchers now have a faster path to target emerging pathogens. This validates generative models for high-stakes biological engineering beyond simple protein folding.